特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

レーバー先天黒内障(LCA):パイプライン製品の分析

Leber Congenital Amaurosis (LCA) - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 293890
出版日 ページ情報 英文 75 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.13円で換算しております。
レーバー先天黒内障(LCA):パイプライン製品の分析 Leber Congenital Amaurosis (LCA) - Pipeline Review, H1 2020
出版日: 2020年03月31日 ページ情報: 英文 75 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

レーバー先天黒内障(LCA)は、主に網膜が侵される眼の疾患です。網膜は、眼球の最も内側にある、光や色を感知する特殊な組織です。小児期の遺伝性の失明で最も多い原因となっています。症状には、失明、眼振、眼のくぼみ、発達遅延、てんかん、運動技能障害などが含まれます。

当レポートでは、レーバー先天黒内障(LCA)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

レーバー先天黒内障(LCA)の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:企業別
  • パイプライン製品:大学/研究機関別
  • 開発中の製品:企業別
  • 調査中の製品:大学/研究機関別

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬の開発に従事している企業

  • AmpliPhi Biosciences Corp
  • Editas Medicine Inc
  • Novelion Therapeutics Inc
  • ProQR Therapeutics NV
  • Spark Therapeutics Inc

薬剤のプロファイル

休止状態のプロジェクト

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for Leber Congenital Amaurosis (LCA), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Leber Congenital Amaurosis (LCA) - Pipeline by Allergan Plc, H1 2020
  • Leber Congenital Amaurosis (LCA) - Pipeline by Generation Bio Corp, H1 2020
  • Leber Congenital Amaurosis (LCA) - Pipeline by IVERIC bio Inc, H1 2020
  • Leber Congenital Amaurosis (LCA) - Pipeline by MeiraGTx Holdings Plc, H1 2020
  • Leber Congenital Amaurosis (LCA) - Pipeline by Ocugen Inc, H1 2020
  • Leber Congenital Amaurosis (LCA) - Pipeline by Odylia Therapeutics Inc, H1 2020
  • Leber Congenital Amaurosis (LCA) - Pipeline by Oxford BioMedica Plc, H1 2020
  • Leber Congenital Amaurosis (LCA) - Pipeline by ProQR Therapeutics NV, H1 2020
  • Leber Congenital Amaurosis (LCA) - Pipeline by Retinagenix LLC, H1 2020
  • Leber Congenital Amaurosis (LCA) - Pipeline by Sanofi, H1 2020
  • Leber Congenital Amaurosis (LCA) - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Leber Congenital Amaurosis (LCA), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
目次
Product Code: GMDHC12077IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leber Congenital Amaurosis (LCA) - Pipeline Review, H1 2020, provides an overview of the Leber Congenital Amaurosis (LCA) (Genetic Disorders) pipeline landscape.

Leber congenital amaurosis is an eye disorder that primarily affects the retina, which is the specialized tissue at the back of the eye that detects light and color. This condition is the most common cause of inherited blindness in childhood. Symptoms include vision loss, roving eye movements, deep-set eyes, developmental delay, epilepsy, and motor skill impairment.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leber Congenital Amaurosis (LCA) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Leber Congenital Amaurosis (LCA) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leber Congenital Amaurosis (LCA) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Leber Congenital Amaurosis (LCA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 3, 6 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.

Leber Congenital Amaurosis (LCA) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leber Congenital Amaurosis (LCA) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Leber Congenital Amaurosis (LCA) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leber Congenital Amaurosis (LCA) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leber Congenital Amaurosis (LCA) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Leber Congenital Amaurosis (LCA) (Genetic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leber Congenital Amaurosis (LCA) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leber Congenital Amaurosis (LCA) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Leber Congenital Amaurosis (LCA) - Overview
  • Leber Congenital Amaurosis (LCA) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Leber Congenital Amaurosis (LCA) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Leber Congenital Amaurosis (LCA) - Companies Involved in Therapeutics Development
  • Allergan Plc
  • Generation Bio Corp
  • IVERIC bio Inc
  • MeiraGTx Holdings Plc
  • Ocugen Inc
  • Odylia Therapeutics Inc
  • Oxford BioMedica Plc
  • ProQR Therapeutics NV
  • Retinagenix LLC
  • Sanofi
  • Leber Congenital Amaurosis (LCA) - Drug Profiles
  • A-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AGN-151587 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy for Leber's Congenital Amaurosis and Stargardt Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate AIPL1 for Leber Congenital Amaurosis and Ophthalmology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate AIPL1 for Leber's Congenital Amaurosis and Retinitis Pigmentosa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate CEP290 for Leber Congenital Amaurosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate Retinal Guanylyl Cyclase-1 for Leber Congenital Amaurosis-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate RPE65 for Leber Congenital Amaurosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate RPE65 for Leber Congenital Amaurosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate RPGRIP1 for Leber Congenital Amaurosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OCU-400 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OXB-204 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • QRX-136 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SAR-439483 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sepofarsen - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • zuretinol acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Leber Congenital Amaurosis (LCA) - Dormant Projects
  • Leber Congenital Amaurosis (LCA) - Product Development Milestones
  • Featured News & Press Releases
  • Mar 04, 2020: Allergan and Editas Medicine announce dosing of first patient in landmark phase 1/2 clinical trial of CRISPR medicine AGN-151587 (EDIT-101) for the treatment of LCA10
  • Jan 13, 2020: Editas Medicine reports presentation on EDIT-101 at J.P. Morgan Healthcare Conference
  • Sep 18, 2019: Ocugen granted FDA orphan drug designation for OCU400 (NR2E3) gene therapy for the treatment of CEP290 mutation associated retinal disease
  • Jul 26, 2019: Allergan and Editas to assess in-vivo CRISPR editing to treat LCA10
  • Apr 29, 2019: Allergan and Editas Medicine announce initial data from natural history study to evaluate patients with leber congenital amaurosis 10 (LCA10)
  • Jan 21, 2019: Editas medicine announces publication in nature medicine of data supporting the development of EDIT-101 to treat Leber Congenital Amaurosis 10 (LCA10)
  • Jan 07, 2019: Editas Medicine reports on recent progress at J.P. Morgan Healthcare Conference
  • Nov 30, 2018: Editas Medicine Announces FDA Acceptance of IND Application for EDIT-101
  • Aug 27, 2018: Editas Medicine announces transition of chief medical officer
  • Aug 16, 2018: Editas Medicine Announces the Completion of the Recombinant DNA Advisory Committee (RAC) Registration Process
  • May 18, 2018: Editas Medicine Reports Data Demonstrating Subretinal Injection of EDIT-101 Well-tolerated in Non-human Primates
  • Oct 19, 2017: Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic Mice
  • Sep 26, 2017: Editas Medicine Receives EMA's Orphan Medicinal Product Designation for EDIT-101 for the Treatment of LCA10
  • Sep 12, 2017: Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10
  • Jan 09, 2017: Editas Medicine Reports on Recent Progress and 2017 Goals at J.P. Morgan Healthcare Conference
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer